Role of ERBT Plus Intravesical BCG in Intermediate-Risk or High-Risk NMBC | MicrobiomeTrials← Back to trialsNCT07724886
Role of ERBT Plus Intravesical BCG in Intermediate-Risk or High-Risk NMBC
RecruitingNAINTERVENTIONAL
Trial Details
Start: 2026-10-19Est. Completion: 2029-12-31
Enrollment target: 732 participants Locations- Prince of Wales Hospital, Hong Kong, Hong Kong
- North District Hospital, Sheung Shui, Hong Kong
ContactYuen Chun Jeremy TEOH
Other microbiome trials you might be interested in
Ganglioneuroblastoma, NodularNeuroblastoma
This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care su…
Birmingham, United StatesEst. completion Dec 31, 2029
Low-grade NMIBCFGFR Gene AmplificationFGFR Gene AlterationsFGFR3 Gene AlterationFGFR3 Gene MutationFGFR3 Gene Fusions
Phase 2 Study of TYRA-300 in FGFR3 Altered Low Grade, Intermediate Risk NMIBC
Homewood, United StatesEst. completion Feb 2028